Mary B. Cranston
Mary B. Cranston's purchase track record
Mary B. Cranston has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/7/2026 | CC | $95K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
TPG Shares Drop Amid Sector Weakness; Analyst Cuts Target to $60. TPG shares fell recently alongside other financial names, reflecting broader market pressure. TD Cowen maintained its positive stance but lowered its price target to $60, citing current market conditions. The stock is trading below its average analyst target, with technical indicators showing it is testing key support levels.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Visa gains record as investors rotate to defensive stocks. Visa and Mastercard posted record highs as investors shifted from chip stocks to more defensive names. The companies have asked a court to approve a fee settlement that could affect their transaction revenue. At the same time, Visa is preparing for a stablecoin payout service, which may broaden its payment offerings. These developments come as the stock trades near the top of its 52‑week range.
Transaction History
| CC | ▲ Buy | Open Market | 6,000 | $95K | 8/7/2026 | View on chart |
| TPG | ▲ Buy | Grant | 4,181 | — | 7/15/2026 | View on chart |
| CC | ▲ Buy | Grant | 7,182 | $0 | 5/6/2026 | View on chart |
| TPG | ▲ Buy | Grant | 2,762 | — | 7/15/2025 | View on chart |
| CC | ▲ Buy | Grant | 14,096 | $0 | 4/22/2025 | View on chart |
| CC | ▲ Buy | Grant | 8,547 | $0 | 8/6/2024 | View on chart |
| TPG | ▲ Buy | Grant | 3,592 | — | 7/15/2024 | View on chart |
| TPG | ▲ Buy | Grant | 5,111 | — | 7/15/2023 | View on chart |
| CC | ▲ Buy | Grant | 5,858 | $0 | 4/26/2023 | View on chart |
| V | ▲ Buy | Grant | 1,050 | $0 | 1/24/2023 | View on chart |
| TPG | ▲ Buy | Grant | 9,142 | — | 7/15/2022 | View on chart |
| V | ▼ Sell | Gift | 940 | $0 | 6/3/2022 | View on chart |
| CC | ▲ Buy | Grant | 4,442 | $0 | 4/27/2022 | View on chart |
| TPG | ▲ Buy | Grant | 10,170 | — | 1/13/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut
Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.